Apnex Medical is a technology company.
Apnex Medical has raised $50.0M across 3 funding rounds.
Apnex Medical has raised $50.0M in total across 3 funding rounds.
Apnex Medical has raised $50.0M in total across 3 funding rounds.
Apnex Medical's investors include Polaris Partners, RiverVest.
# Apnex Medical: High-Level Overview
Apnex Medical is a medical device company, not a technology company in the traditional sense. The company specialized in developing an implantable medical device for treating obstructive sleep apnea (OSA), a chronic breathing disorder affecting millions globally.[1][2] Founded in 2006 and based in the Twin Cities (St. Paul/Roseville, Minnesota), Apnex developed the Hypoglossal Nerve Stimulation (HGNS) System, an active implant that stimulates the hypoglossal nerve to keep the upper airway open during sleep.[1]
However, it's important to note that Apnex Medical has ceased operations. The company shut down after raising over $50 million in venture capital when early clinical trial results proved disappointing, and it became clear the company would not meet primary endpoints in a key clinical trial.[6]
# Origin Story
Apnex Medical was founded in 2006 with a mission to pioneer medical innovations for patients with sleep disordered breathing.[5] The company's founding emerged from recognizing a significant unmet need: obstructive sleep apnea affects millions of patients, and existing treatment options (such as CPAP machines) have poor long-term compliance rates.
The company achieved notable early traction, securing CE Mark approval in Europe for its HGNS System, demonstrating regulatory validation of the technology.[4] This European approval represented a pivotal moment, suggesting the device had cleared a significant regulatory hurdle. However, subsequent clinical trial results in what appears to be a U.S. trial did not validate the therapy's effectiveness as hoped, leading co-founder Michael Berman and leadership to make the difficult decision to wind down operations.[6]
# Core Differentiators
# Role in the Broader Medical Device Landscape
Apnex operated within the growing neuromodulation and sleep medicine sectors, riding the trend toward implantable solutions for chronic conditions. The timing was favorable—sleep apnea treatment represents a multi-billion-dollar market with significant unmet needs. However, the company's closure underscores a critical reality in medical device development: regulatory approval and early feasibility do not guarantee clinical efficacy or commercial success. The failure to meet primary trial endpoints highlights the high bar for implantable therapies and the substantial clinical evidence required for market adoption.
# Quick Take & Future Outlook
Apnex Medical's story is one of innovation meeting clinical reality. While the company successfully developed a novel technology and secured European regulatory approval, it ultimately could not demonstrate sufficient clinical benefit to justify continued investment and commercialization. The company's closure serves as a cautionary tale in medtech: promising early-stage results and venture capital funding are necessary but insufficient conditions for success. The broader sleep apnea treatment market continues to evolve, with other companies pursuing alternative neuromodulation approaches and pharmaceutical interventions to address this significant patient population.
Apnex Medical has raised $50.0M across 3 funding rounds. Most recently, it raised $20.0M Series C in February 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2012 | $20.0M Series C | Polaris Partners | |
| Dec 1, 2009 | $14.0M Series B | Polaris Partners | |
| May 1, 2007 | $16.0M Series A | Polaris Partners, RiverVest |